LSE - Delayed Quote USD
Arbutus Biopharma Corporation (0SGC.L)
3.3188
+0.0100
+(0.30%)
At close: January 31 at 2:52:18 PM GMT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in CAD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | 2.22M | 2.19M | 7.85M | 6.18M |
| Low Estimate | 1.4M | 1.26M | 5.18M | 3.92M |
| High Estimate | 2.52M | 2.52M | 9.92M | 9.86M |
| Year Ago Sales | 2.39M | 1.86M | 8.8M | 7.85M |
| Sales Growth (year/est) | -6.92% | 18.02% | -10.84% | -21.28% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 0SGC.L | -- | -- | -- | -- |
| S&P 500 | 13.32% | 2.61% | 7.73% | 13.77% |
Upgrades & Downgrades
| Maintains | Chardan Capital: Buy to Buy | 3/28/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/21/2025 |
| Maintains | Chardan Capital: Buy to Buy | 11/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/7/2024 |
| Maintains | Chardan Capital: Buy to Buy | 11/7/2024 |